Table 2 Factors associated with OS in all patients diagnosed with stage IIIB–IV NSCLC in 2012–2016
Parameter | Patients, n (%) | Factors associated with OSa | |
|---|---|---|---|
N = 1008 | HR (95% CI) | P value | |
Age at NSCLC diagnosis in years | < 0.001 | ||
< 65 | 478 (47.4) | 1.00 (ref) | |
65–74 | 307 (30.5) | 1.12 (0.96–1.32) | |
≥ 75 | 223 (22.1) | 1.50 (1.26–1.79) | |
Sex | 0.045 | ||
Male | 762 (75.6) | 1.00 (ref) | |
Female | 246 (24.4) | 0.83 (0.70–0.996) | |
TNM stage and brain metastasis at diagnosis | < 0.001 | ||
Stage IIIB | 154 (15.3) | 1.00 (ref) | |
Stage IV without brain metastasis | 691 (68.6) | 1.56 (1.26–1.94) | |
Stage IV with brain metastasis | 163 (16.2) | 2.92 (2.25–3.79) | |
Histology and mutations/rearrangement | < 0.001 | ||
NSQ | 720 (71.4) | – | |
NSQ EGFR and ALK wildtype | 476 (47.2) | 1.00 (ref) | |
NSQ EGFR or ALK mutations/rearrangements | 142 (14.1) | 0.49 (0.38–0.63) | |
NSQ EGFR/ALK not tested | 102 (10.1) | 1.57 (1.25–1.98) | |
SQ | 210 (20.8) | 1.14 (0.95–1.38) | |
NSCLC NOS/Others | 78 (7.7) | 1.43 (1.11–1.84) | |